Baillie Gifford & Company Upped By $895,644 Its Brown (BF.B) Holding; Synergy Pharmaceuticals DE (SGYP) Shorts Decreased By 4.77%

February 15, 2018 - By Nellie Frank

Baillie Gifford & Company increased Brown (BF.B) stake by 3.94% reported in 2017Q3 SEC filing. Baillie Gifford & Company acquired 16,586 shares as Brown (BF.B)’s stock 0.00%. The Baillie Gifford & Company holds 438,032 shares with $23.79 million value, up from 421,446 last quarter. Brown now has $25.83B valuation. The stock increased 0.69% or $0.46 during the last trading session, reaching $67.34. About 655,768 shares traded. Brown-Forman Corporation (NYSE:BF.B) has risen 11.07% since February 15, 2017 and is uptrending. It has underperformed by 5.63% the S&P500.

Synergy Pharmaceuticals DE (NASDAQ:SGYP) had a decrease of 4.77% in short interest. SGYP’s SI was 76.15 million shares in February as released by FINRA. Its down 4.77% from 79.97 million shares previously. With 7.11M avg volume, 11 days are for Synergy Pharmaceuticals DE (NASDAQ:SGYP)’s short sellers to cover SGYP’s short positions. The SI to Synergy Pharmaceuticals DE’s float is 44.04%. The stock decreased 2.84% or $0.06 during the last trading session, reaching $2.05. About 4.92 million shares traded. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has risen 24.44% since February 15, 2017 and is uptrending. It has outperformed by 7.74% the S&P500.

Among 12 analysts covering Brown-Forman (NYSE:BF.B), 0 have Buy rating, 2 Sell and 10 Hold. Therefore 0 are positive. Brown-Forman had 37 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was downgraded by Credit Suisse on Thursday, June 8 to “Hold”. Cowen & Co maintained Brown-Forman Corporation (NYSE:BF.B) rating on Thursday, August 31. Cowen & Co has “Hold” rating and $54.0 target. Stifel Nicolaus maintained it with “Hold” rating and $74.0 target in Friday, December 22 report. RBC Capital Markets maintained Brown-Forman Corporation (NYSE:BF.B) on Tuesday, October 3 with “Hold” rating. Sterne Agee CRT downgraded the shares of BF.B in report on Friday, February 26 to “Neutral” rating. The stock of Brown-Forman Corporation (NYSE:BF.B) has “Hold” rating given on Friday, June 23 by RBC Capital Markets. Cowen & Co maintained the stock with “Hold” rating in Wednesday, December 6 report. RBC Capital Markets maintained Brown-Forman Corporation (NYSE:BF.B) rating on Wednesday, December 6. RBC Capital Markets has “Hold” rating and $61.0 target. The stock has “Sector Perform” rating by RBC Capital Markets on Monday, January 4. As per Tuesday, July 25, the company rating was maintained by RBC Capital Markets.

Baillie Gifford & Company decreased Anthem Inc (NYSE:ANTM) stake by 24,989 shares to 4.93M valued at $936.52M in 2017Q3. It also reduced Moody’s Corp (NYSE:MCO) stake by 53,592 shares and now owns 6.76 million shares. Lincoln Electric Hdg. (NASDAQ:LECO) was reduced too.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. The company has market cap of $505.65 million. The Company’s lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. It currently has negative earnings. The firm also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Synergy Pharmaceuticals had 40 analyst reports since August 25, 2015 according to SRatingsIntel. The rating was maintained by Citigroup on Wednesday, September 13 with “Sell”. Cantor Fitzgerald maintained Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) on Tuesday, November 21 with “Buy” rating. The company was downgraded on Thursday, April 6 by Citigroup. As per Monday, January 22, the company rating was maintained by Oppenheimer. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by BTIG Research on Tuesday, August 1. The stock has “Buy” rating by BTIG Research on Monday, June 26. The firm has “Buy” rating given on Friday, December 23 by Rodman & Renshaw. The stock has “Buy” rating by BTIG Research on Friday, January 26. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has “Buy” rating given on Thursday, August 10 by Oppenheimer. The stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by H.C. Wainwright on Monday, September 25.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Nellie Frank

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: